CBIO — Crescent Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $308.08m
- $98.89m
- $10.84m
Annual cashflow statement for Crescent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -63.4 | -46.7 | -36.9 | -37.9 | -154 |
| Depreciation | |||||
| Non-Cash Items | 6.84 | 4.69 | 4.43 | 5.59 | 95.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.17 | -4.66 | -2.56 | 1.16 | -13.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -57.5 | -46.5 | -34.9 | -31.1 | -71.5 |
| Capital Expenditures | -0.015 | -0.084 | -0.021 | -0.01 | -72.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | 0.03 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.015 | -0.084 | -0.021 | 0.02 | -72.9 |
| Financing Cash Flow Items | — | — | — | — | 1.27 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.7 | 4.16 | 28.8 | 0.005 | 323 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -46.8 | -42.4 | -6.08 | -31.1 | 179 |